[Pharmacokinetic study of flubendazole in human hydatid disease caused by Echinococcus granulosus. Preliminary results (author's transl)].
A pharmacokinetic study of flubendazole was carried out, using a radioimmunological method, in patients with hydatid disease about to undergo surgery; there was no evidence of drug penetration into the walls or contents of the cysts. Another study, carried out simultaneously in subjects without hydatid disease, showed very high concentrations of the drug in liver tissue and in bile. These results should not be taken as arguments against the effectiveness of flubendazole, but should encourage the setting up of further randomized pharmacokinetic studies.
D000328:Adult; D000923:Anticestodal Agents / Q000378:metabolism*; D001562:Benzimidazoles / Q000378:metabolism*; D004443:Echinococcosis / Q000378:metabolism*; D004444:Echinococcosis, Hepatic / Q000378:metabolism; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D008463:Mebendazole / Q000031:analogs & derivatives / Q000378:metabolism*; D011863:Radioimmunoassay; D013158:Splenic Diseases / Q000378:metabolism
D000923:Anticestodal Agents; D001562:Benzimidazoles; D008463:Mebendazole; C018945:flubendazole
Etude pharmacocinétique du flubendazole au cours de l'hydatidose humaine à E. granulosus. Résultats préliminaires.